J Rheum Dis.  2019 Jan;26(1):1-4. 10.4078/jrd.2019.26.1.1.

Early Detection of Pulmonary Hypertension in Connective Tissue Disease

• Jeon CH

• KMID: 2442028
• DOI: http://doi.org/10.4078/jrd.2019.26.1.1

Abstract

No abstract available.

MeSH Terms

Connective Tissue Diseases*
Connective Tissue*
Hypertension, Pulmonary*

Reference

1. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62:25 Suppl. D42–D50.

2. Bhatnagar A, Wiesen J, Dweik R, Chaisson NF. Evaluating suspected pulmonary hypertension: a structured approach. Cleve Clin J Med. 2018; 85:468–480.

3. Lau EM, Manes A, Celermajer DS, Galiè N. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J. 2011; 32:2489–2498.

4. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37:67–119.

5. Maron BA, Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol. 2016; 1:1056–1065.

6. Hoeper MM, Simon R. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev. 2014; 23:450–457.

7. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009; 179:151–157.

8. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J. 2007; 30:1103–1110.

9. Aithala R, Alex AG, Danda D. Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis. 2017; 20:5–24.

10. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122:164–172.

11. Haddad RN, Mielniczuk LM. An evidence-based approach to screening and diagnosis of pulmonary hypertension. Can J Cardiol. 2015; 31:382–390.

12. Jung JY, Lee CH, Kim HA, Choi ST, Lee JH, Yoon BY, et al. Pulmonary hypertension in connective tissue disease is associated with the New York Heart Association functional class and forced vital capacity, but not with interstitial lung disease. J Rheum Dis. 2018; 25:179–187.

13. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003; 48:516–522.

14. Avouac J, Airò P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010; 37:2290–2298.

15. Condliffe R, Howard LS. Connective tissue disease-associated pulmonary arterial hypertension. F1000Prime Rep. 2015; 7:06.

16. Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev. 2011; 10:248–255.

17. Michelfelder M, Becker M, Riedlinger A, Siegert E, Drömann D, Yu X, et al. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin Rheumatol. 2017; 36:381–390.

18. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008; 177:1248–1254.

19. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, et al. Pulmonary hypertension due to chronic lung disease: updated recommendations of the Cologne consensus conference 2011. Int J Cardiol. 2011; 154:Suppl 1. S45–S53.

20. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M. Australian Scleroderma Interest Group (ASIG). Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med. 2016; 16:134.

21. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013; 65:2412–2423.

22. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52:3792–3800.

23. Iudici M, Codullo V, Giuggioli D, Riccieri V, Cuomo G, Breda S, et al. Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clin Exp Rheumatol. 2013; 31:2 Suppl 76. 31–36.

24. Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum. 2014; 44:55–62.

25. Hinchcliff M, Fischer A, Schiopu E, Steen VD. PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol. 2011; 38:2172–2179.

26. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol. 2004; 43:764–770.

27. Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther. 2012; 14:R143.

28. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008; 58:284–291.

29. Odler B, Foris V, Gungl A, Müller V, Hassoun PM, Kwapiszewska G, et al. Biomarkers for pulmonary vascular remodeling in systemic sclerosis: a pathophysiological approach. Front Physiol. 2018; 9:587.

30. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2008; 32:503–512.

31. Affandi AJ, Radstake TR, Marut W. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol. 2015; 37:475–487.

32. Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med. 2014; 190:808–817.

33. Thakkar V, Lau EM. Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol. 2016; 30:22–38.

34. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014; 73:1340–1349.